Postoperative subconjunctival bevacizumab injection as an adjunct to 5-fluorouracil in the management of scarring after trabeculectomy

Clinical Ophthalmology

Volumn 7, Issue , 2013, Pages 1211-1217

  Joyce Freiberg, Florentina ^a   Matlach, Juliane ^a   Grehn, Franz ^a   Karl, Sabine ^a   Klink, Thomas ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

5 Fluorouracil; Bevacizumab; Bleb failure; Bleb scarring; Glaucoma; Trabeculectomy

Indexed keywords

BEVACIZUMAB; DEXASINE SE; FLUOROURACIL; MITOMYCIN; PREDNISOLONE; STEROID; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLEB SCARRING; CLOSED ANGLE GLAUCOMA; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LOW TENSION GLAUCOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; OPEN ANGLE GLAUCOMA; PERIMETRY; PIGMENT DISPERSION GLAUCOMA; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PSEUDOEXFOLIATION GLAUCOMA; RETROSPECTIVE STUDY; SCAR FORMATION; SURGICAL TECHNIQUE; TRABECULECTOMY; VISUAL ACUITY;

EID: 84879322379     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S41750     Document Type: Article

References (24)

1. O'Brien C, Schwartz B, Takamoto T, Wu DC. Intraocular pressure and the rate of visual field loss in chronic open-angle glaucoma. Am J Ophthalmol. 1991;111(4):491-500.
2. Cairns JE. Trabeculectomy. Preliminary report of a new method. Am J Ophthalmol. 1968;66(4):673-679.
3. Reddick R, Merritt JC, Ross G, Avery A, Peiffer RL. Myofibroblasts in filtration operations. Ann Ophthalmol. 1985;17(3):200-203.
4. Mostafaei A. Augmenting trabeculectomy in glaucoma with subconjunctival mitomycin C versus subconjunctival 5-fluorouracil: a randomized clinical trial. Clin Ophthalmol. 2011;5:491-494.
5. Greenfield DS, Suñer IJ, Miller MP, Kangas TA, Palmberg PF, Flynn HW Jr. Endophthalmitis after filtering surgery with mitomycin. Arch Ophthalmol. 1996;114(8):943-949.
6. Seah SK, Prata JA Jr, Minckler DS, Baerveldt G, Lee PP, Heuer DK. Hypotony following trabeculectomy. J Glaucoma. 1995;4(2): 73-79.
7. Bao P, Kodra A, Tomic-Canic M, Golinko MS, Ehrlich HP, Brem H. The role of vascular endothelial growth factor in wound healing. J Surg Res. 2009;153(2):347-358.
8. Nissen NN, Polverini PJ, Koch AE, Volin MV, Gamelli RL, DiPietro LA. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol. 1998;152(6):1445-1452.
9. Lopilly Park HY, Kim JH, Ahn MD, Park CK. Level of vascular endothelial growth factor in tenon tissue and results of glaucoma surgery. Arch Ophthalmol. 2012;130(6):685-689.
10. Tripathi RC, Li J, Tripathi BJ, Chalam KV, Adamis AP. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology. 1998;105(2):232-237.
11. Hu DN, Ritch R, Liebmann J, Liu Y, Cheng B, Hu MS. Vascular endothelial growth factor is increased in aqueous humor of glaucomatous eyes. J Glaucoma. 2002;11(5):406-410.
12. Miyake T, Sawada O, Kakinoki M, et al. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes. Invest Ophthalmol Vis Sci. 2010;51(3):1606-1608.
13. Kahook MY, Schuman JS, Noecker RJ. Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging. 2006;37(2):144-146.
14. Grewal DS, Jain R, Kumar H, Grewal SP. Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy a pilot study. Ophthalmology. 2008;115(12):2141. e2-2145. e2.
15. Nilforushan N, Yadgari M, Kish SK, Nassiri N. Subconjunctival bevacizumab versus mitomycin C adjunctive to trabeculectomy. Am J Ophthalmol. 2012;153(2):e1352-e1357.
16. How A, Chua JL, Charlton A, et al. Combined treatment with bevacizumab and 5-fluorouracil attenuates the postoperative scarring response after experimental glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 2010;51(2):928-932.
17. Memarzadeh F, Varma R, Lin LT, et al. Postoperative use of bevacizumab as an antifibrotic agent in glaucoma filtration surgery in the rabbit. Invest Ophthalmol Vis Sci. 2009;50(7):3233-3237.
18. Klink T, Schrey S, Elsesser U, Klink J, Schlunck G, Grehn F. Interobserver variability of the Wurzburg bleb classification score. Ophthalmologica. 2008;222(6):408-413.
19. Klink T, Kann G, Ellinger P, Klink J, Grehn F, Guthoff R. The prognostic value of the Wuerzburg bleb classification score for the outcome of trabeculectomy. Ophthalmologica. 2011;225(1):55-60.
20. Esson DW, Popp MP, Liu L, Schultz GS, Sherwood MB. Microarray analysis of the failure of filtering blebs in a rat model of glaucoma filtering surgery. Invest Ophthalmol Vis Sci. 2004;45(12):4450-4462.
21. Li Z, Van Bergen T, Van de Veire S, et al. Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 2009;50(11):5217-5225.
22. Mathew R, Barton K. Anti-vascular endothelial growth factor therapy in glaucoma filtration surgery. Am J Ophthalmol. 2011;152(1): e210-e215.
23. O'Neill EC, Qin Q, Van Bergen NJ, et al. Antifibrotic activity of bevacizumab on human Tenon's fibroblasts in vitro. Invest Ophthalmol Vis Sci. 2010;51(12):6524-6532.
24. Nomoto H, Shiraga F, Kuno N, et al. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci. 2009;50(10):4807-4813.